<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23685637</PMID><DateCompleted><Year>2013</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2013</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0293</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>7</Issue><PubDate><Year>2013</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Critical care medicine</Title><ISOAbbreviation>Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Milrinone therapy for enterovirus 71-induced pulmonary edema and/or neurogenic shock in children: a randomized controlled trial.</ArticleTitle><Pagination><StartPage>1754</StartPage><EndPage>1760</EndPage><MedlinePgn>1754-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/CCM.0b013e31828a2a85</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Enterovirus 71-induced brainstem encephalitis with pulmonary edema and/or neurogenic shock (stage 3B) is associated with rapid mortality in children. In a small pilot study, we found that milrinone reduced early mortality compared with historical controls. This prospective, randomized control trial was designed to provide more definitive evidence of the ability of milrinone to reduce the 1-week mortality of stage 3B enterovirus 71 infections.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective, unicenter, open-label, randomized, controlled study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Inpatient ward of a large tertiary teaching hospital in Ho Chi Minh City, Vietnam.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Children (&#x2264; 18 yr old) admitted with proven enterovirus 71-induced pulmonary edema and/or neurogenic shock.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Patients were randomly assigned to receive intravenous milrinone (0.5 &#x3bc;g/kg/min) (n = 22) or conventional management (n = 19). Both groups received dopamine or dobutamine and intravenous immunoglobulin.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS" NlmCategory="RESULTS">The primary endpoint was 1-week mortality. The secondary endpoints included length of ventilator dependence and hospital stay and adverse events. The median age was 2 years with a predominance of boys in both groups. The 1-week mortality was significantly lower, 18.2% (4/22) in the milrinone compared with 57.9% (11/19) in the conventional management group (relative risk = 0.314 [95% CI, 0.12-0.83], p = 0.01). The median duration of ventilator-free days was longer in the milrinone treatment group (p = 0.01). There was no apparent neurologic sequela in the survivors in either group, and no drug-related adverse events were documented.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Milrinone significantly reduced the 1-week mortality of enterovirus 71-induced pulmonary edema and/or neurogenic shock without adverse effects. Further studies are needed to determine whether milrinone might be useful to prevent progression of earlier stages of brainstem encephalitis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chi</LastName><ForeName>Chia-Yu</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli County, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khanh</LastName><ForeName>Truong Huu</ForeName><Initials>TH</Initials></Author><Author ValidYN="Y"><LastName>Thoa</LastName><ForeName>Le Phan Kim</ForeName><Initials>le PK</Initials></Author><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>Fan-Chen</ForeName><Initials>FC</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shih-Min</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Thinh</LastName><ForeName>Le Quoc</ForeName><Initials>le Q</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chia-Chun</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Han-Chieh</ForeName><Initials>HC</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jen-Ren</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Hung</LastName><ForeName>Nguyen Thanh</ForeName><Initials>NT</Initials></Author><Author ValidYN="Y"><LastName>Thuong</LastName><ForeName>Tang Chi</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Chung-Ming</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Ih-Jen</ForeName><Initials>IJ</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ching-Chuan</ForeName><Initials>CC</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ISRCTN</DataBankName><AccessionNumberList><AccessionNumber>ISRCTN76926623</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Crit Care Med</MedlineTA><NlmUniqueID>0355501</NlmUniqueID><ISSNLinking>0090-3493</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002316">Cardiotonic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007136">Immunoglobulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>3S12J47372</RegistryNumber><NameOfSubstance UI="D004280">Dobutamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>JU9YAX04C7</RegistryNumber><NameOfSubstance UI="D020105">Milrinone</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Crit Care Med. 2013 Jul;41(7):1821-2. doi: 10.1097/CCM.0b013e318291cb2d</RefSource><PMID Version="1">23774351</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Crit Care Med. 2013 Nov;41(11):e390-1. doi: 10.1097/CCM.0b013e31829e4e38</RefSource><PMID Version="1">24162695</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Crit Care Med. 2013 Nov;41(11):e391-2. doi: 10.1097/CCM.0b013e3182a264d1</RefSource><PMID Version="1">24162696</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002316" MajorTopicYN="N">Cardiotonic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004280" MajorTopicYN="N">Dobutamine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007136" MajorTopicYN="N">Immunoglobulins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007262" MajorTopicYN="N">Infusions, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020105" MajorTopicYN="N">Milrinone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011654" MajorTopicYN="N">Pulmonary Edema</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012769" MajorTopicYN="N">Shock</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014744" MajorTopicYN="N" Type="Geographic">Vietnam</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23685637</ArticleId><ArticleId IdType="doi">10.1097/CCM.0b013e31828a2a85</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>